title: Epidemiology of vancomycin-resistant enterococci with reduced susceptibility to daptomycin.
abstract: A retrospective case-case control study was conducted, including 60 cases with daptomycin-nonsusceptible vancomycin-resistant enterococci (DNS-VRE) matched to cases with daptomycin-susceptible VRE and to uninfected controls (1∶1∶3 ratio). Immunosuppression, presence of comorbid conditions, and prior exposure to antimicrobials were independent predictors of DNS-VRE, although prior daptomycin exposure occurred rarely. In summary, a case-case control study identified independent risk factors for the isolation of DNS-VRE: immunosuppression, multiple comorbid conditions, and prior exposures to cephalosporines and metronidazole.
authors.affiliation: Department of Pharmacy Services, Detroit Medical Center, Detroit, Michigan, USA.
authors.forename: Theresa
authors.initials: T
authors.lastname: Judge
authors.forename: Jason M
authors.initials: JM
authors.lastname: Pogue
authors.forename: Dror
authors.initials: D
authors.lastname: Marchaim
authors.forename: Kevin
authors.initials: K
authors.lastname: Ho
authors.forename: Srinivasa
authors.initials: S
authors.lastname: Kamatam
authors.forename: Shakila
authors.initials: S
authors.lastname: Parveen
authors.forename: Namita
authors.initials: N
authors.lastname: Tiwari
authors.forename: Priyanka
authors.initials: P
authors.lastname: Nanjireddy
authors.forename: Suchitha
authors.initials: S
authors.lastname: Bheemreddy
authors.forename: Caitlin
authors.initials: C
authors.lastname: Biedron
authors.forename: Sagar Mallikethi Lepakshi
authors.initials: SM
authors.lastname: Reddy
authors.forename: Vijaykumar
authors.initials: V
authors.lastname: Khammam
authors.forename: Indu K
authors.initials: IK
authors.lastname: Chalana
authors.forename: Rajachendra Shekher
authors.initials: RS
authors.lastname: Tumma
authors.forename: Vicki
authors.initials: V
authors.lastname: Collins
authors.forename: Adnan
authors.initials: A
authors.lastname: Yousuf
authors.forename: Paul R
authors.initials: PR
authors.lastname: Lephart
authors.forename: Emily T
authors.initials: ET
authors.lastname: Martin
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Rybak
authors.forename: Keith S
authors.initials: KS
authors.lastname: Kaye
authors.forename: Kayoko
authors.initials: K
authors.lastname: Hayakawa
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016022:Case-Control Studies; D002511:Cephalosporins / Q000627:therapeutic use; D015897:Comorbidity; D017576:Daptomycin / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial; D013293:Enterococcus faecalis / Q000187:drug effects*; D016984:Enterococcus faecium / Q000187:drug effects*; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000453:epidemiology* / Q000382:microbiology; D006801:Humans; D007165:Immunosuppression Therapy; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D018709:Statistics, Nonparametric; D014640:Vancomycin / Q000494:pharmacology*; D020713:Vancomycin Resistance
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D008795:Metronidazole; D014640:Vancomycin; D017576:Daptomycin